PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) outlined a strategic pipeline re-prioritization and shared its financial results for the year 2024. This move aims to focus on potentially groundbreaking programs while extending the company’s cash runway into the fourth quarter of 2026.
Key priorities include advancing four core programs engineered with the company’s proprietary Allo-Evasion™ 5.0 technology. CNTY-308, targeting B-cell mediated autoimmune diseases and cancers, leads the pipeline. Additional efforts are concentrated on CNTY-101, which has shown transformational potential in autoimmune diseases, with Phase 1 CALiPSO-1 trial data expected in 2025.
“Today we announced a pipeline re-prioritization to streamline resources on advancing candidates that are potentially transformational or best-in-class in diseases with high unmet need. We ended the year with a strong cash position, which we will leverage to achieve meaningful milestones and drive value for all stakeholders as we take the company forward in a new direction,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics.
Clinical Updates
- The Phase 1 CALiPSO-1 trial has begun enrollment in the U.S., with plans to expand into Europe in mid-2025. Five sites are actively screening patients, with the first dosing slated for March 2025.
- The company’s CARAMEL investigator-initiated trial (IIT), sponsored by Friedrich-Alexander University Erlangen-Nürnberg, will evaluate CNTY-101 in B-cell mediated autoimmune diseases. The trial is expected to launch in mid-2025 after Clinical Trial Authorization (CTA) approval.
- The ELiPSE-1 Phase 1 program for late-stage relapsed-refractory non-Hodgkin’s lymphoma has been discontinued. The decision reflects emerging clinical data that does not meet the company’s standard for transformational impact in this indication. However, the trial highlighted encouraging potential in autoimmune diseases, reinforcing CNTY-101’s relevance for the CALiPSO-1 trial.
“We have made the strategic decision to discontinue the Phase 1 ELiPSE-1 trial early, and we thank the patients, providers and caregivers for their support and participation. We believe CNTY-101 is well-positioned to potentially impact the standard of care meaningfully in B-cell-mediated autoimmune diseases,” Pfeiffenberger said.
Preclinical Initiatives
The pipeline re-prioritization also includes advancing CNTY-308 into IND-enabling studies by mid-2025. Additional programs include CD19/CD22 dual-targeted CAR-iT cell therapy (CNTY-341), and a solid tumor CAR-iT program focusing on Nectin-4 CAR with enhanced engineering to address tumor resistance.
Chad Cowan, Ph.D., Chief Scientific Officer, commented on the strategic preclinical efforts. “We believe these exciting programs unlock an opportunity to replace current therapies and expand application of cell therapy to areas with serious medical need, starting with what we believe to be our unique ab CD4+/CD8+ CAR-T cells combined with our most advanced Allo-Evasion™ 5.0 technology.”
Financial Performance
Century Therapeutics’ cash, cash equivalents, and marketable securities amounted to $220.1 million as of December 31, 2024, compared to $261.8 million a year earlier. Operating expenses increased due to clinical trial progression and manufacturing costs, leading to a net loss of $126.6 million for 2024, compared to $136.7 million in 2023. Collaboration revenue from Bristol-Myers Squibb contributed $6.6 million.
The company plans to host a webcast on April 22 to detail its reprioritized pipeline. With a renewed strategic focus, Century Therapeutics underscores its ambition to pioneer advances in cell therapy across autoimmune diseases and cancer.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.